Evaluation of Long-term Efficacy of Treatment With Lamazym

Key facts

Sponsor

Zymenex A/S

Principal Investigator

Allan M Lund, MD

Copenhagen University Hospital, Center for Metabolic Diseases, Department of Clinical Genetics

Intervention

Lamazym(drug)

Enrollment

18 enrolled

Eligibility

All sexes

Timeline

2015 – 2015

Study locations (1)

• Center for Metabolic Diseases, Department of Clinical Genetics, Juliane Marie Centre, Copenhagen University Hospital, Blegdamsvej 9, Copenhagen, Denmark

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Alpha-mannosidosis

Additional recruiting or active studies for the same condition.

• RECRUITINGNCT06184503
  Analysis of Velmanase Alfa (Lamzede®)'s Effects in the Body of Children With Alpha-Mannosidosis Under the Age 3
  Chiesi Farmaceutici S.p.A.

See all trials for Alpha-mannosidosis →